On September 10, 2026 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, reported that William Ho, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, on Monday, September 14, 2026, in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Ho and members of the IN8bio management team will host one-on-one meetings with investors throughout the conference.

H.C. Wainwright 28th Annual Global Investment Conference
Date: Monday, September 14, 2026
Time: 10:00 a.m. ET
Format: Fireside Chat
Presenter: William Ho, Chief Executive Officer and Co-Founder
Location: Kennedy II, 4th Floor, Lotte New York Palace Hotel, New York City
Webcast: Webcast Link

A live webcast of the presentation will be available through the Investors section of IN8bio’s website. A replay will be available following the event.

(Press release, In8bio, SEP 10, 2026, View Source [SID1234670729])

On September 10, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported it will present a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development taking place September 25-28, 2026, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:
Title: Atebimetinib Reduces Tumor Volume and Preserves Body Mass: A Dual Mechanism for Extended Survival in Pancreatic Cancer
Presenter: Peter Vu, M.D., MHA, UC San Diego Health
Poster Number: A134
Session Date: Saturday, September 26, 2026
Session Time: 6:00 – 8:00 pm PT
Location: Indigo CDCH

The abstract will be available on the AACR (Free AACR Whitepaper) website. Following presentation, the poster will be available on the publications section of Immuneering’s website at View Source

(Press release, Immuneering, SEP 10, 2026, View Source [SID1234670728])

On September 10, 2026 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, reported that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will feature results from the recurrent ovarian cancer cohort of the large Phase 1b C-800-01 study, including patients with platinum-refractory/resistant disease, with analyses by platinum sensitivity status and long-term three-year overall survival.

Presentation Details:

Abstract Title: Next Generation Immune Checkpoint Inhibition with Botensilimab Plus Balstilimab in Recurrent Ovarian Cancer: Results by Platinum Sensitivity Status and 3-Year Overall Survival
Presenter: Rebecca L. Porter, M.D.; Dana-Farber Cancer Institute, Boston, MA, USA
Poster Presentation number: 969
Session Title: Poster Rounds with Professors Session, Ovarian Cancer 03 Session
Date/Time: Saturday, October 3, 2026 | 10:50am-10:55am EDT

(Press release, Agenus, SEP 10, 2026, View Source [SID1234670727])

On September 10, 2026 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, reported that Oren Gilad, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Webcast link: Click here available from 4:30pm ET on Monday, September 14, 2026

Investors can register for the conference here. Those interested in arranging a one-on-one meeting with management should contact their H.C. Wainwright representative.

(Press release, Aprea, SEP 10, 2026, View Source [SID1234670726])

On September 10, 2026 Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, reported that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT13722, an oral KAT6A selective degrader being developed for the treatment of patients with HR+/HER2- breast cancer. The Company expects to begin enrolling patients in the fourth quarter of 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations," stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. "Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies may limit the utility in earlier lines of treatment. Our approach of selectively degrading KAT6A has the potential to address this challenge by maximizing the therapeutic window with enhanced efficacy and improved hematological safety, as supported by our preclinical data. We look forward to advancing PRT13722 into the clinic with the ultimate goal of providing a new therapeutic option for patients with HR+/HER2- breast cancer."

The Phase 1 study is a first-in-human, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of PRT13722 as monotherapy and in combination with endocrine and targeted therapies in adults with locally advanced or metastatic HR-positive, HER2-negative breast cancer.

Highly selective KAT6A oral degrader program

KAT6 is an emerging and clinically validated target in the treatment of ER+ breast cancer. Prelude discovered and is developing first-in-class, highly potent, highly selective and orally bioavailable KAT6A degraders. Prelude believes that selectively degrading KAT6A and sparing KAT6B has the potential for improved efficacy, tolerability and combinability with other agents relative to dual inhibitors of KAT6A/B.

(Press release, Prelude Therapeutics, SEP 10, 2026, View Source [SID1234670725])